140 results on '"Baklaushev, Vladimir P."'
Search Results
2. Large-scale assessment of pros and cons of autopsy-derived or tumor-matched tissues as the norms for gene expression analysis in cancers
- Author
-
Sorokin, Maksim, Buzdin, Anton A., Guryanova, Anastasia, Efimov, Victor, Suntsova, Maria V., Zolotovskaia, Marianna A., Koroleva, Elena V., Sekacheva, Marina I., Tkachev, Victor S., Garazha, Andrew, Kremenchutckaya, Kristina, Drobyshev, Aleksey, Seryakov, Aleksander, Gudkov, Alexander, Alekseenko, Irina V., Rakitina, Olga, Kostina, Maria B., Vladimirova, Uliana, Moisseev, Aleksey, Bulgin, Dmitry, Radomskaya, Elena, Shestakov, Viktor, Baklaushev, Vladimir P., Prassolov, Vladimir, Shegay, Petr V., Li, Xinmin, Poddubskaya, Elena V., and Gaifullin, Nurshat
- Published
- 2023
- Full Text
- View/download PDF
3. Effect of vitamin D3 supplementation on cellular immunity and inflammatory markers in COVID-19 patients admitted to the ICU
- Author
-
Bychinin, Mikhail V., Klypa, Tatiana V., Mandel, Irina A., Yusubalieva, Gaukhar M., Baklaushev, Vladimir P., Kolyshkina, Nadezhda A., and Troitsky, Aleksandr V.
- Published
- 2022
- Full Text
- View/download PDF
4. Incidence and prognosis of distant metastasis in malignant peripheral nerve sheath tumors
- Author
-
Xu, Yao, Xu, Guijun, Liu, Zheng, Duan, Jincai, Lin, Yile, Zhu, Jiajia, Baklaushev, Vladimir P., Chekhonin, Vladimir P., Peltzer, Karl, Wang, Guowen, Wang, Xin, and Zhang, Chao
- Published
- 2021
- Full Text
- View/download PDF
5. Non-Tumor Cells within the Tumor Microenvironment—The "Eminence Grise" of the Glioblastoma Pathogenesis and Potential Targets for Therapy.
- Author
-
Bugakova, Aleksandra S., Chudakova, Daria A., Myzina, Maria S., Yanysheva, Elvira P., Ozerskaya, Iuliia V., Soboleva, Alesya V., Baklaushev, Vladimir P., and Yusubalieva, Gaukhar M.
- Subjects
TUMOR microenvironment ,GLIOBLASTOMA multiforme ,PROGNOSIS ,CENTRAL nervous system ,CELL populations - Abstract
Glioblastoma (GBM) is the most common malignancy of the central nervous system in adults. GBM has high levels of therapy failure and its prognosis is usually dismal. The phenotypic heterogeneity of the tumor cells, dynamic complexity of non-tumor cell populations within the GBM tumor microenvironment (TME), and their bi-directional cross-talk contribute to the challenges of current therapeutic approaches. Herein, we discuss the etiology of GBM, and describe several major types of non-tumor cells within its TME, their impact on GBM pathogenesis, and molecular mechanisms of such an impact. We also discuss their value as potential therapeutic targets or prognostic biomarkers, with reference to the most recent works on this subject. We conclude that unless all "key player" populations of non-tumor cells within the TME are considered, no breakthrough in developing treatment for GBM can be achieved. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Age Prediction Using DNA Methylation Heterogeneity Metrics.
- Author
-
Karetnikov, Dmitry I., Romanov, Stanislav E., Baklaushev, Vladimir P., and Laktionov, Petr P.
- Subjects
DNA methylation ,AGE factors in disease ,WHOLE genome sequencing ,DISEASE risk factors ,HETEROGENEITY - Abstract
Dynamic changes in genomic DNA methylation patterns govern the epigenetic developmental programs and accompany the organism's aging. Epigenetic clock (eAge) algorithms utilize DNA methylation to estimate the age and risk factors for diseases as well as analyze the impact of various interventions. High-throughput bisulfite sequencing methods, such as reduced-representation bisulfite sequencing (RRBS) or whole genome bisulfite sequencing (WGBS), provide an opportunity to identify the genomic regions of disordered or heterogeneous DNA methylation, which might be associated with cell-type heterogeneity, DNA methylation erosion, and allele-specific methylation. We systematically evaluated the applicability of five scores assessing the variability of methylation patterns by evaluating within-sample heterogeneity (WSH) to construct human blood epigenetic clock models using RRBS data. The best performance was demonstrated by the model based on a metric designed to assess DNA methylation erosion with an MAE of 3.686 years. We also trained a prediction model that uses the average methylation level over genomic regions. Although this region-based model was relatively more efficient than the WSH-based model, the latter required the analysis of just a few short genomic regions and, therefore, could be a useful tool to design a reduced epigenetic clock that is analyzed by targeted next-generation sequencing. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials
- Author
-
Axfors, Cathrine, Janiaud, Perrine, Schmitt, Andreas M., van’t Hooft, Janneke, Smith, Emily R., Haber, Noah A., Abayomi, Akin, Abduljalil, Manal, Abdulrahman, Abdulkarim, Acosta-Ampudia, Yeny, Aguilar-Guisado, Manuela, Al-Beidh, Farah, Alejandria, Marissa M., Alfonso, Rachelle N., Ali, Mohammad, AlQahtani, Manaf, AlZamrooni, Alaa, Anaya, Juan-Manuel, Ang, Mark Angelo C., Aomar, Ismael F., Argumanis, Luis E., Averyanov, Alexander, Baklaushev, Vladimir P., Balionis, Olga, Benfield, Thomas, Berry, Scott, Birocco, Nadia, Bonifacio, Lynn B., Bowen, Asha C., Bown, Abbie, Cabello-Gutierrez, Carlos, Camacho, Bernardo, Camacho-Ortiz, Adrian, Campbell-Lee, Sally, Cao, Damon H., Cardesa, Ana, Carnate, Jose M., Castillo, German Jr. J., Cavallo, Rossana, Chowdhury, Fazle R., Chowdhury, Forhad U. H., Ciccone, Giovannino, Cingolani, Antonella, Climacosa, Fresthel Monica M., Compernolle, Veerle, Cortez, Carlo Francisco N., Costa Neto, Abel, D’Antico, Sergio, Daly, James, Danielle, Franca, Davis, Joshua S., De Rosa, Francesco Giuseppe, Denholm, Justin T., Denkinger, Claudia M., Desmecht, Daniel, Díaz-Coronado, Juan C., Díaz Ponce-Medrano, Juan A., Donneau, Anne-Françoise, Dumagay, Teresita E., Dunachie, Susanna, Dungog, Cecile C., Erinoso, Olufemi, Escasa, Ivy Mae S., Estcourt, Lise J., Evans, Amy, Evasan, Agnes L. M., Fareli, Christian J., Fernandez-Sanchez, Veronica, Galassi, Claudia, Gallo, Juan E., Garcia, Patricia J., Garcia, Patricia L., Garcia, Jesus A., Garigliany, Mutien, Garza-Gonzalez, Elvira, Gauiran, Deonne Thaddeus V., Gaviria García, Paula A., Giron-Gonzalez, Jose-Antonio, Gómez-Almaguer, David, Gordon, Anthony C., Gothot, André, Grass Guaqueta, Jeser Santiago, Green, Cameron, Grimaldi, David, Hammond, Naomi E., Harvala, Heli, Heralde, Francisco M., Herrick, Jesica, Higgins, Alisa M., Hills, Thomas E., Hines, Jennifer, Holm, Karin, Hoque, Ashraful, Hoste, Eric, Ignacio, Jose M., Ivanov, Alexander V., Janssen, Maike, Jennings, Jeffrey H., Jha, Vivekanand, King, Ruby Anne N., Kjeldsen-Kragh, Jens, Klenerman, Paul, Kotecha, Aditya, Krapp, Fiorella, Labanca, Luciana, Laing, Emma, Landin-Olsson, Mona, Laterre, Pierre-François, Lim, Lyn-Li, Lim, Jodor, Ljungquist, Oskar, Llaca-Díaz, Jorge M., López-Robles, Concepción, López-Cárdenas, Salvador, Lopez-Plaza, Ileana, Lucero, Josephine Anne C., Lundgren, Maria, Macías, Juan, Maganito, Sandy C., Malundo, Anna Flor G., Manrique, Rubén D., Manzini, Paola M., Marcos, Miguel, Marquez, Ignacio, Martínez-Marcos, Francisco Javier, Mata, Ana M., McArthur, Colin J., McQuilten, Zoe K., McVerry, Bryan J., Menon, David K., Meyfroidt, Geert, Mirasol, Ma. Angelina L., Misset, Benoît, Molton, James S., Mondragon, Alric V., Monsalve, Diana M., Moradi Choghakabodi, Parastoo, Morpeth, Susan C., Mouncey, Paul R., Moutschen, Michel, Müller-Tidow, Carsten, Murphy, Erin, Najdovski, Tome, Nichol, Alistair D., Nielsen, Henrik, Novak, Richard M., O’Sullivan, Matthew V. N., Olalla, Julian, Osibogun, Akin, Osikomaiya, Bodunrin, Oyonarte, Salvador, Pardo-Oviedo, Juan M., Patel, Mahesh C., Paterson, David L., Peña-Perez, Carlos A., Perez-Calatayud, Angel A., Pérez-Alba, Eduardo, Perkina, Anastasia, Perry, Naomi, Pouladzadeh, Mandana, Poyato, Inmaculada, Price, David J., Quero, Anne Kristine H., Rahman, Md. M., Rahman, Md. S., Ramesh, Mayur, Ramírez-Santana, Carolina, Rasmussen, Magnus, Rees, Megan A., Rego, Eduardo, Roberts, Jason A., Roberts, David J., Rodríguez, Yhojan, Rodríguez-Baño, Jesús, Rogers, Benjamin A., Rojas, Manuel, Romero, Alberto, Rowan, Kathryn M., Saccona, Fabio, Safdarian, Mehdi, Santos, Maria Clariza M., Sasadeusz, Joe, Scozzari, Gitana, Shankar-Hari, Manu, Sharma, Gorav, Snelling, Thomas, Soto, Alonso, Tagayuna, Pedrito Y., Tang, Amy, Tatem, Geneva, Teofili, Luciana, Tong, Steven Y. C., Turgeon, Alexis F., Veloso, Januario D., Venkatesh, Balasubramanian, Ventura-Enriquez, Yanet, Webb, Steve A., Wiese, Lothar, Wikén, Christian, Wood, Erica M., Yusubalieva, Gaukhar M., Zacharowski, Kai, Zarychanski, Ryan, Khanna, Nina, Moher, David, Goodman, Steven N., Ioannidis, John P. A., and Hemkens, Lars G.
- Published
- 2021
- Full Text
- View/download PDF
8. Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern
- Author
-
Gorchakov, Andrey A., Kulemzin, Sergey V., Guselnikov, Sergey V., Baranov, Konstantin O., Belovezhets, Tatyana N., Mechetina, Ludmila V., Volkova, Olga Yu., Najakshin, Alexander M., Chikaev, Nikolai A., Chikaev, Anton N., Solodkov, Pavel P., Larichev, Victor F., Gulyaeva, Marina A., Markhaev, Alexander G., Kononova, Yulia V., Alekseyev, Alexander Yu., Shestopalov, Alexander M., Yusubalieva, Gaukhar M., Klypa, Tatiana V., Ivanov, Alexander V., Valuev-Elliston, Vladimir T., Baklaushev, Vladimir P., and Taranin, Alexander V.
- Published
- 2021
- Full Text
- View/download PDF
9. Nomogram for predicting overall survival in colorectal cancer with distant metastasis
- Author
-
Liu, Zheng, Xu, Yao, Xu, Guijun, Baklaushev, Vladimir P., Chekhonin, Vladimir P., Peltzer, Karl, Ma, Wenjuan, Wang, Xin, Wang, Guowen, and Zhang, Chao
- Published
- 2021
- Full Text
- View/download PDF
10. Highly photostable fluorescent labeling of proteins in live cells using exchangeable coiled coils heterodimerization
- Author
-
Perfilov, Maxim M., Gurskaya, Nadya G., Serebrovskaya, Ekaterina O., Melnikov, Pavel A., Kharitonov, Sergey L., Lewis, Tylor R., Arshavsky, Vadim Y., Baklaushev, Vladimir P., Mishin, Alexander S., and Lukyanov, Konstantin A.
- Published
- 2020
- Full Text
- View/download PDF
11. The incidence, associated factors, and predictive nomogram for early death in stage IV colorectal cancer
- Author
-
Wang, Xin, Mao, Min, Xu, Guijun, Lin, Feng, Sun, Peng, Baklaushev, Vladimir P., Chekhonin, Vladimir P., Peltzer, Karl, Zhang, Jin, and Zhang, Chao
- Published
- 2019
- Full Text
- View/download PDF
12. Patterns of bone metastases in newly diagnosed colorectal cancer: a real-world analysis in the SEER database
- Author
-
Guo, Xu, Zhang, Chao, Ma, Wenjuan, Tian, Fei, Xu, Guijun, Han, Xiuxin, Sun, Peng, Baklaushev, Vladimir P., Bryukhovetskiy, Andrey S., Wang, Guowen, Ma, Yulin, and Wang, Xin
- Published
- 2019
- Full Text
- View/download PDF
13. Improving Efficiency of Direct Pro-Neural Reprogramming: Much-Needed Aid for Neuroregeneration in Spinal Cord Injury.
- Author
-
Chudakova, Daria A., Samoilova, Ekaterina M., Chekhonin, Vladimir P., and Baklaushev, Vladimir P.
- Subjects
SPINAL cord injuries ,CYTOLOGY ,CENTRAL nervous system injuries ,ELECTRIC stimulation ,SOMATIC cells ,PROGENITOR cells - Abstract
Spinal cord injury (SCI) is a medical condition affecting ~2.5–4 million people worldwide. The conventional therapy for SCI fails to restore the lost spinal cord functions; thus, novel therapies are needed. Recent breakthroughs in stem cell biology and cell reprogramming revolutionized the field. Of them, the use of neural progenitor cells (NPCs) directly reprogrammed from non-neuronal somatic cells without transitioning through a pluripotent state is a particularly attractive strategy. This allows to "scale up" NPCs in vitro and, via their transplantation to the lesion area, partially compensate for the limited regenerative plasticity of the adult spinal cord in humans. As recently demonstrated in non-human primates, implanted NPCs contribute to the functional improvement of the spinal cord after injury, and works in other animal models of SCI also confirm their therapeutic value. However, direct reprogramming still remains a challenge in many aspects; one of them is low efficiency, which prevents it from finding its place in clinics yet. In this review, we describe new insights that recent works brought to the field, such as novel targets (mitochondria, nucleoli, G-quadruplexes, and others), tools, and approaches (mechanotransduction and electrical stimulation) for direct pro-neural reprogramming, including potential ones yet to be tested. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. MRI Guiding of the Middle Cerebral Artery Occlusion in Rats Aimed to Improve Stroke Modeling
- Author
-
Gubskiy, Ilya L., Namestnikova, Daria D., Cherkashova, Elvira A., Chekhonin, Vladimir P., Baklaushev, Vladimir P., Gubsky, Leonid V., and Yarygin, Konstantin N.
- Published
- 2018
- Full Text
- View/download PDF
15. Nomogram based on homogeneous and heterogeneous associated factors for predicting bone metastases in patients with different histological types of lung cancer
- Author
-
Zhang, Chao, Mao, Min, Guo, Xu, Cui, Ping, Zhang, Lianmin, Xu, Yao, Li, Lili, Han, Xiuxin, Peltzer, Karl, Xiong, Shunbin, Baklaushev, Vladimir P., Wang, Xin, and Wang, Guowen
- Published
- 2019
- Full Text
- View/download PDF
16. Human Mesenchymal Stem Cells Modified with the NS5A Gene of Hepatitis C Virus Induce a Cellular Immune Response Exceeding the Response to DNA Immunization with This Gene.
- Author
-
Masalova, Olga V., Lesnova, Ekaterina I., Kalsin, Vladimir A., Klimova, Regina R., Fedorova, Natalya E., Kozlov, Vyacheslav V., Demidova, Natalya A., Yurlov, Kirill I., Konoplyannikov, Mikhail A., Nikolaeva, Tatyana N., Pronin, Alexander V., Baklaushev, Vladimir P., and Kushch, Alla A.
- Subjects
HUMAN stem cells ,HEPATITIS C virus ,MESENCHYMAL stem cells ,MYELOID-derived suppressor cells ,CD8 antigen ,IMMUNE response - Abstract
Simple Summary: Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV). Chronic viral hepatitis C is asymptomatic for many years and can lead to the development of liver cirrhosis/cancer. A vaccine is needed to eliminate hepatitis C; however, numerous attempts to create vaccines have so far been unsuccessful. The aim of this work was to investigate the ability of genetically modified human mesenchymal stem cells (mMSCs) expressing the HCV NS5A protein to induce a cellular immune response to HCV. Sixteen stem cell lines of a various origin were tested, and MSCs obtained from the dental pulp were selected which most effectively expressed the HCV protein. The triple immunization of mice with mMSCs showed an increase in the antigen-specific lymphocyte proliferation, the greater production of antiviral cytokine interferon-gamma, as well as an increase in the number of CD4+ memory T cells compared with the immunization with the NS5A gene. Thus, these results, which were obtained for the first time, show that human mMSCs can be a basis for the development of an effective vaccine against hepatitis C that triggers a strong T cell response and prevents the transition of acute hepatitis C to the chronic form due to the rapid activation of memory cells. Hepatitis C virus (HCV) is one of the basic culprits behind chronic liver disease, which may result in cirrhosis and hepatocarcinoma. In spite of the extensive research conducted, a vaccine against HCV has not been yet created. We have obtained human mesenchymal stem cells (hMSCs) and used them for expressing the HCV NS5A protein as a model vaccination platform. Sixteen hMSC lines of a different origin were transfected with the pcNS5A-GFP plasmid to obtain genetically modified MSCs (mMSCs). The highest efficiency was obtained by the transfection of dental pulp MSCs. C57BL/6 mice were immunized intravenously with mMSCs, and the immune response was compared with the response to the pcNS5A-GFP plasmid, which was injected intramuscularly. It was shown that the antigen-specific lymphocyte proliferation and the number of IFN-γ-synthesizing cells were two to three times higher after the mMSC immunization compared to the DNA immunization. In addition, mMSCs induced more CD4+ memory T cells and an increase in the CD4+/CD8+ ratio. The results suggest that the immunostimulatory effect of mMSCs is associated with the switch of MSCs to the pro-inflammatory phenotype and a decrease in the proportion of myeloid derived suppressor cells. Thus, the possibility of using human mMSCs for the creation of a vaccine against HCV has been shown for the first time. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Recombinant Strains of Oncolytic Vaccinia Virus for Cancer Immunotherapy.
- Author
-
Shakiba, Yasmin, Vorobyev, Pavel O., Mahmoud, Marah, Hamad, Azzam, Kochetkov, Dmitriy V., Yusubalieva, Gaukhar M., Baklaushev, Vladimir P., Chumakov, Peter M., and Lipatova, Anastasia V.
- Subjects
VACCINIA ,ONCOGENIC viruses ,ONCOLYTIC virotherapy ,KILLER cells ,IMMUNOTHERAPY ,BIOENGINEERING ,T cells - Abstract
Cancer virotherapy is an alternative therapeutic approach based on the viruses that selectively infect and kill tumor cells. Vaccinia virus (VV) is a member of the Poxviridae, a family of enveloped viruses with a large linear double-stranded DNA genome. The proven safety of the VV strains as well as considerable transgene capacity of the viral genome, make VV an excellent platform for creating recombinant oncolytic viruses for cancer therapy. Furthermore, various genetic modifications can increase tumor selectivity and therapeutic efficacy of VV by arming it with the immune-modulatory genes or proapoptotic molecules, boosting the host immune system, and increasing cross-priming recognition of the tumor cells by T-cells or NK cells. In this review, we summarized the data on bioengineering approaches to develop recombinant VV strains for enhanced cancer immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Alterations in the CD56 − and CD56 + T Cell Subsets during COVID-19.
- Author
-
Vavilova, Julia D., Ustiuzhanina, Maria O., Boyko, Anna A., Streltsova, Maria A., Kust, Sofya A., Kanevskiy, Leonid M., Iskhakov, Rustam N., Sapozhnikov, Alexander M., Gubernatorova, Ekaterina O., Drutskaya, Marina S., Bychinin, Mikhail V., Novikova, Oksana N., Sotnikova, Anna G., Yusubalieva, Gaukhar M., Baklaushev, Vladimir P., and Kovalenko, Elena I.
- Subjects
COVID-19 pandemic ,CYTOTOXIC T cells ,T cells ,KILLER cells ,INTENSIVE care units ,CELL death ,COVID-19 - Abstract
The effectiveness of the antiviral immune response largely depends on the activation of cytotoxic T cells. The heterogeneous group of functionally active T cells expressing the CD56 molecule (NKT-like cells), that combines the properties of T lymphocytes and NK cells, is poorly studied in COVID-19. This work aimed to analyze the activation and differentiation of both circulating NKT-like cells and CD56
− T cells during COVID-19 among intensive care unit (ICU) patients, moderate severity (MS) patients, and convalescents. A decreased proportion of CD56+ T cells was found in ICU patients with fatal outcome. Severe COVID-19 was accompanied by a decrease in the proportion of CD8+ T cells, mainly due to the CD56− cell death, and a redistribution of the NKT-like cell subset composition with a predominance of more differentiated cytotoxic CD8+ T cells. The differentiation process was accompanied by an increase in the proportions of KIR2DL2/3+ and NKp30+ cells in the CD56+ T cell subset of COVID-19 patients and convalescents. Decreased percentages of NKG2D+ and NKG2A+ cells and increased PD-1 and HLA-DR expression levels were found in both CD56− and CD56+ T cells, and can be considered as indicators of COVID-19 progression. In the CD56− T cell fraction, increased CD16 levels were observed in MS patients and in ICU patients with lethal outcome, suggesting a negative role for CD56− CD16+ T cells in COVID-19. Overall, our findings suggest an antiviral role of CD56+ T cells in COVID-19. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
19. Oncolytic Efficacy of a Recombinant Vaccinia Virus Strain Expressing Bacterial Flagellin in Solid Tumor Models.
- Author
-
Shakiba, Yasmin, Vorobyev, Pavel O., Naumenko, Victor A., Kochetkov, Dmitry V., Zajtseva, Ksenia V., Valikhov, Marat P., Yusubalieva, Gaukhar M., Gumennaya, Yana D., Emelyanov, Egor A., Semkina, Alevtina S., Baklaushev, Vladimir P., Chumakov, Peter M., and Lipatova, Anastasia V.
- Subjects
VACCINIA ,FLAGELLIN ,RECOMBINANT viruses ,VIBRIO vulnificus ,LUCIFERASES ,FLUORESCENT proteins - Abstract
Oncolytic viral therapy is a promising novel approach to cancer treatment. Oncolytic viruses cause tumor regression through direct cytolysis on the one hand and recruiting and activating immune cells on the other. In this study, to enhance the antitumor efficacy of the thymidine kinase-deficient vaccinia virus (VV, Lister strain), recombinant variants encoding bacterial flagellin (subunit B) of Vibrio vulnificus (LIVP-FlaB-RFP), firefly luciferase (LIVP-Fluc-RFP) or red fluorescent protein (LIVP-RFP) were developed. The LIVP-FLuc-RFP strain demonstrated exceptional onco-specificity in tumor-bearing mice, detected by the in vivo imaging system (IVIS). The antitumor efficacy of these variants was explored in syngeneic murine tumor models (B16 melanoma, CT26 colon cancer and 4T1 breast cancer). After intravenous treatment with LIVP-FlaB-RFP or LIVP-RFP, all mice tumor models exhibited tumor regression, with a prolonged survival rate in comparison with the control mice. However, superior oncolytic activity was observed in the B16 melanoma models treated with LIVP-FlaB-RFP. Tumor-infiltrated lymphocytes and the cytokine analysis of the serum and tumor samples from the melanoma-xenografted mice treated with these virus variants demonstrated activation of the host's immune response. Thus, the expression of bacterial flagellin by VV can enhance its oncolytic efficacy against immunosuppressive solid tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. SARS-CoV-2 Establishes a Productive Infection in Hepatoma and Glioblastoma Multiforme Cell Lines.
- Author
-
Smirnova, Olga A., Ivanova, Olga N., Fedyakina, Irina T., Yusubalieva, Gaukhar M., Baklaushev, Vladimir P., Yanvarev, Dmitry V., Kechko, Olga I., Mitkevich, Vladimir A., Vorobyev, Pavel O., Fedorov, Vyacheslav S., Bartosch, Birke, Valuev-Elliston, Vladimir T., Lipatova, Anastasiya L., and Ivanov, Alexander V.
- Subjects
CELL differentiation ,COVID-19 ,GLIOMAS ,BRAIN tumors ,GENE expression ,INTERFERONS ,RESEARCH funding ,CELL lines ,LIVER cells ,HEPATOCELLULAR carcinoma ,ANGIOTENSIN converting enzyme - Abstract
Simple Summary: A novel coronavirus that causes a worldwide pandemic poses a significant threat to patients. The virus can induce not only a cytokine storm and thrombosis but also various extra-respiratory diseases such as liver dysfunction, strong headaches, loss of smell and even psychiatric disorders. However, information on whether SARS-CoV-2 can infect liver or brain tissues is still contradictory. Here, we show that the coronavirus efficiently infects liver cancer cells but does not replicate in non-tumor hepatocyte-like cells. SARS-CoV-2 was also found to infect some glioblastoma cells, which is the most common type of brain tumor. In conclusion, we show that SARS-CoV-2 can infect tumor tissues. Severe acute respiratory syndrome associated coronavirus 2 (SARS-CoV-2) emerged at the end of 2019 and rapidly caused a pandemic that led to the death of >6 million people due to hypercoagulation and cytokine storm. In addition, SARS-CoV-2 triggers a wide array of pathologies, including liver dysfunction and neurological disorders. It remains unclear if these events are due to direct infection of the respective tissues or result from systemic inflammation. Here, we explored the possible infection of hepatic and CNS cell lines by SARS-CoV-2. We show that even moderate expression levels of the angiotensin-converting enzyme 2 (ACE2) are sufficient for productive infection. SARS-CoV-2 infects hepatoma Huh7.5 and HepG2 cells but not non-transformed liver progenitor or hepatocyte/cholangiocyte-like HepaRG cells. However, exposure to the virus causes partial dedifferentiation of HepaRG cells. SARS-CoV-2 can also establish efficient replication in some low-passage, high-grade glioblastoma cell lines. In contrast, embryonal primary astrocytes or neuroblastoma cells did not support replication of the virus. Glioblastoma cell permissiveness is associated with defects in interferon production. Overall, these results suggest that liver dysfunction during COVID-19 is not due to infection of these tissues by SARS-CoV-2. Furthermore, tumors may potentially serve as reservoirs for the virus during infection. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies.
- Author
-
Hamad, Azzam, Yusubalieva, Gaukhar M., Baklaushev, Vladimir P., Chumakov, Peter M., and Lipatova, Anastasiya V.
- Subjects
ONCOLYTIC virotherapy ,GLIOBLASTOMA multiforme ,BRAIN tumors ,MEDICAL protocols ,VIROTHERAPY - Abstract
Glioblastoma is the most aggressive form of malignant brain tumor. Standard treatment protocols and traditional immunotherapy are poorly effective as they do not significantly increase the long-term survival of glioblastoma patients. Oncolytic viruses (OVs) may be an effective alternative approach. Combining OVs with some modern treatment options may also provide significant benefits for glioblastoma patients. Here we review virotherapy for glioblastomas and describe several OVs and their combination with other therapies. The personalized use of OVs and their combination with other treatment options would become a significant area of research aiming to develop the most effective treatment regimens for glioblastomas. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. Coordinated Loss and Acquisition of NK Cell Surface Markers Accompanied by Generalized Cytokine Dysregulation in COVID-19.
- Author
-
Ustiuzhanina, Maria O., Vavilova, Julia D., Boyko, Anna A., Streltsova, Maria A., Kust, Sofya A., Kanevskiy, Leonid M., Sapozhnikov, Alexander M., Iskhakov, Rustam N., Gubernatorova, Ekaterina O., Drutskaya, Marina S., Bychinin, Mikhail V., Zhukova, Oksana A., Novikova, Oksana N., Sotnikova, Anna G., Yusubalieva, Gaukhar M., Baklaushev, Vladimir P., and Kovalenko, Elena I.
- Subjects
KILLER cells ,COVID-19 ,COVID-19 pandemic ,SARS-CoV-2 ,INTENSIVE care units - Abstract
Coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, is accompanied by a dysregulated immune response. In particular, NK cells, involved in the antiviral response, are affected by the infection. This study aimed to investigate circulating NK cells with a focus on their activation, depletion, changes in the surface expression of key receptors, and functional activity during COVID-19, among intensive care unit (ICU) patients, moderately ill patients, and convalescents (CCP). Our data confirmed that NK cell activation in patients with COVID-19 is accompanied by changes in circulating cytokines. The progression of COVID-19 was associated with a coordinated decrease in the proportion of NKG2D
+ and CD16+ NK cells, and an increase in PD-1, which indicated their exhaustion. A higher content of NKG2D+ NK cells distinguished surviving patients from non-survivors in the ICU group. NK cell exhaustion in ICU patients was additionally confirmed by a strong negative correlation of PD-1 and natural cytotoxicity levels. In moderately ill patients and convalescents, correlations were found between the levels of CD57, NKG2C, and NKp30, which may indicate the formation of adaptive NK cells. A reduced NKp30 level was observed in patients with a lethal outcome. Altogether, the phenotypic changes in circulating NK cells of COVID-19 patients suggest that the intense activation of NK cells during SARS-CoV-2 infection, most likely induced by cytokines, is accompanied by NK cell exhaustion, the extent of which may be critical for the disease outcome. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
23. Studying the genotoxic effects of high intensity terahertz radiation on fibroblasts and CNS tumor cells.
- Author
-
Sitnikov, Dmitry S., Revkova, Veronika A., Ilina, Inna V., Gurova, Svetlana A., Komarov, Pavel S., Struleva, Evgenia V., Konoplyannikov, Mikhail A., Kalsin, Vladimir A., and Baklaushev, Vladimir P.
- Abstract
The data is obtained on the effect of high‐intensity pulses of terahertz (THz) radiation with a broad spectrum (0.2–3 THz) on cell cultures. We have evaluated the threshold exposure parameters of THz radiation causing genotoxic effects in fibroblasts. Phosphorylation of histone H2AX at Ser 139 (γH2AX) was chosen as a marker for genotoxicity and a quantitative estimation of γH2AX foci number in fibroblasts was performed after cell irradiation with THz pulses for 30 min. No genotoxic effects of THz radiation were observed in fibroblasts unless peak intensity and electric field strength exceeded 21 GW cm−2 and 2.8 MV cm−1, respectively. In tumor cell lines (neuroblastoma (SK‐N‐BE (2)) and glioblastoma (U87)), exposure to THz pulses with peak intensity of 21 GW cm−2 for 30 min caused no morphological changes as well as no statistically significant increase in histone phosphorylation foci number. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Targeted delivery of liposomal nanocontainers to the peritumoral zone of glioma by means of monoclonal antibodies against GFAP and the extracellular loop of Cx43
- Author
-
Chekhonin, Vladimir P., Baklaushev, Vladimir P., Yusubalieva, Gaukhar M., Belorusova, Anastasia E., Gulyaev, Michael V., Tsitrin, Eugene B., Grinenko, Nadezhda F., Gurina, Olga I., and Pirogov, Yuriy A.
- Published
- 2012
- Full Text
- View/download PDF
25. Functional Profiling of In Vitro Reactivated Memory B Cells Following Natural SARS-CoV-2 Infection and Gam-COVID-Vac Vaccination.
- Author
-
Astakhova, Ekaterina A., Byazrova, Maria G., Yusubalieva, Gaukhar M., Kulemzin, Sergey V., Kruglova, Natalia A., Prilipov, Alexey G., Baklaushev, Vladimir P., Gorchakov, Andrey A., Taranin, Alexander V., and Filatov, Alexander V.
- Subjects
IMMUNOLOGIC memory ,COVID-19 vaccines ,VACCINATION ,COVID-19 ,NATURAL immunity ,VIRAL antibodies ,B cells ,IMMUNOGLOBULINS - Abstract
Both SARS-CoV-2 infection and vaccination have previously been demonstrated to elicit robust, yet somewhat limited immunity against the evolving variants of SARS-CoV-2. Nevertheless, reports performing side-by-side comparison of immune responses following infection vs. vaccination have been relatively scarce. The aim of this study was to compare B-cell response to adenovirus-vectored vaccination in SARS-CoV-2-naive individuals with that observed in the COVID-19 convalescent patients six months after the first encounter with the viral antigens. We set out to use a single analytical platform and performed comprehensive analysis of serum levels of receptor binding domain (RBD)-specific and virus-neutralizing antibodies, frequencies of RBD-binding circulating memory B cells (MBCs), MBC-derived antibody-secreting cells, as well as RBD-specific and virus-neutralizing activity of MBC-derived antibodies after Gam-COVID-Vac (Sputnik V) vaccination and/or natural SARS-CoV-2 infection. Overall, natural immunity was superior to Gam-COVID-Vac vaccination. The levels of neutralizing MBC-derived antibodies in the convalescent patients turned out to be significantly higher than those found following vaccination. Our results suggest that after six months, SARS-CoV-2-specific MBC immunity is more robust in COVID-19 convalescent patients than in Gam-COVID-Vac recipients. Collectively, our data unambiguously indicate that natural immunity outperforms Gam-COVID-Vac-induced immunity six months following recovery/vaccination, which should inform healthcare and vaccination decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. Targeted Transport of 125I-Labeled Antibody to GFAP and AMVB1 in an Experimental Rat Model of C6 Glioma
- Author
-
Chekhonin, Vladimir P., Baklaushev, Vladimir P., Yusubalieva, Gaukhar M., and Gurina, Olga I.
- Published
- 2009
- Full Text
- View/download PDF
27. Risk and Prognostic Factors for Different Organ Metastasis in Primary Osteosarcoma: A Large Population‐Based Analysis.
- Author
-
Xu, Guijun, Wu, Haixiao, Zhang, Yanting, Xu, Yao, Guo, Xu, Baklaushev, Vladimir P., Chekhonin, Vladimir P., Peltzer, Karl, Wang, Jun, Lu, Feng, Wang, Guowen, Wang, Xin, Ma, Wenjuan, and Zhang, Chao
- Subjects
PROGNOSIS ,OSTEOSARCOMA ,PROOF & certification of death ,OLDER patients ,OVERALL survival - Abstract
Objective: Based on a large public cohort, we aimed to investigate the prevalence of distant metastases in patients with osteosarcoma, to evaluate the survival of patients with different metastases and to reveal the related risk and prognostic factors for distant metastases. Methods: The information of osteosarcoma patients with or without distant metastases was retrospectively extracted from the Surveillance, Epidemiology, and End Result database from January 2010 to December 2015. Patients were excluded if they were diagnosed at autopsy or via death certification. The Kaplan–Meier method was used to calculate the overall survival in the entire cohort and across patients with metastases to different organs. The related prognostic factors were investigated by univariate and multivariate Cox proportional hazard regression analysis. The logistic regression method was used to reveal the risk factors for the development of different metastases. The effects of different variables on the survival and prevalence of distant metastases were compared using subgroup analysis. Variables with P < 0.05 in the univariate regression analysis were further examined using multivariate regression analysis. Results: In total, 1470 osteosarcoma patients (mean age 30 ± 22 years) were included, among which 278 patients (18.9%) were initially diagnosed with distant metastasis. The median follow‐up duration was 33.0 (30.2–35.8) months. The lung was the most common metastatic site (83.8%), followed by the bone (21.9%), liver (2.9%), and brain (2.2%). A total of 232 patients (83.5%) presented only one distant metastatic site, while the other 46 patients showed two or more metastatic sites. A lower proportion of metastasis was observed in patients aged from 25 to 59 years [odds ratio (OR) = 0.59; 95% confidence interval (CI): 0.37–0.95]. More metastases were noted in patients with T2/T1 (OR = 1.91; 95% CI: 1.28–2.84), T3/T1 (OR = 4.48; 95% CI: 1.78–11.30) and N1/N0 stages (OR = 6.66; 95% CI: 2.68–16.56). The 1‐, 3‐, and 5‐year overall survival rates for metastatic patients were 57.3% (95% CI: 50.8%–63.8%), 25.3% (95% CI: 18.8%–31.9%), and 18.1% (95% CI: 10.2%–26.0%), respectively. Metastatic patients older than 25 years were prone to have poor survival and a relatively better prognosis (hazard ratio = 0.41; 95% CI: 0.25–0.69) was noticed among those who underwent surgery on the primary site. Different metastatic organs have homogeneous and heterogeneous risk and prognostic factors. Conclusion: The high incidence of initial distant metastasis in osteosarcoma and the inconsistent predictive factors should be given more attention in the clinical management of patients with osteosarcoma. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. Racial disparities in bone metastasis patterns and targeted screening and treatment strategies in newly diagnosed lung cancer patients.
- Author
-
Xu, Guijun, Cui, Ping, Zhang, Chao, Lin, Feng, Xu, Yao, Guo, Xu, Cai, Jun, Baklaushev, Vladimir P., Peltzer, Karl, Chekhonin, Vladimir P., Wang, Xin, and Wang, Guowen
- Subjects
RACISM ,PUBLIC health surveillance ,STATISTICS ,HEALTH services accessibility ,CONFIDENCE intervals ,MULTIPLE regression analysis ,HEALTH status indicators ,EARLY detection of cancer ,LUNG tumors ,LYMPH nodes ,QUANTITATIVE research ,CANCER patients ,TUMOR classification ,INCOME ,BONE metastasis ,SURVIVAL analysis (Biometry) ,DISEASE prevalence ,DESCRIPTIVE statistics ,CHI-squared test ,KAPLAN-Meier estimator ,WHITE people ,STATISTICAL correlation ,PROPORTIONAL hazards models ,INSURANCE - Abstract
Objective: Race disparities exist in bone metastasis (BM) development and survival in lung cancer (LC) patients. The Surveillance, Epidemiology, and End Results (SEER) database was used to investigate different patterns of BM development and survival in different races. Design: LC patients with BM were identified from the database from 2010 to 2014. Risk factors were investigated by univariable and multivariable logistic regression. Potential factors for prognosis were evaluated by univariable and multivariable Cox regression. Results: Asian and Pacific Islander (API) patients presented the highest prevalence of BM (24.6%), followed by white (20.7%) and black patients (19.9%) (χ2 = 78.74; p <.001). After adjusting for the demographic and clinical factors, API race was independently associated with a high risk of BM development. The median survival times for the API, white and black LC patients with BM were 16 months (95% CI: 15.2–16.8), 11 months (95% CI: 10.9–11.1) and 10 months (95% CI: 9.7–10.3), respectively, with significant differences (p <.001). Multivariable Cox regression showed that API race was positively associated with greater overall survival compared with white and black patients. Male gender, larger tumor size, lymph node involvement, lower tumor differentiated grade, and the presence of lung, liver and brain metastases were independently associated with a high risk of developing BM and worse survival with LC across all races. Age, income, insurance and histological types had different impacts on BM among different races. Conclusion: Homogeneous and heterogeneous associated factors for BM were revealed among different races. Individualized screening and treatment should be performed race-specifically. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. Abstracts from the 3rd Conference on Aneuploidy and Cancer: Clinical and Experimental Aspects
- Author
-
Cornish-Bowden, Athel, Rasnick, David, Heng, Henry H, Horne, Steven, Abdallah, Batoul, Liu, Guo, Ye, Christine J, Bloomfield, Mathew, Vincent, Mark D, Aldaz, C. M, Karlsson, Jenny, Valind, Anders, Jansson, Caroline, Gisselsson, David, Graves, Jennifer A M, Stepanenko, Aleksei A, Andreieva, Svitlana V, Korets, Kateryna V, Mykytenko, Dmytro O, Huleyuk, Nataliya L, Baklaushev, Vladimir P, Kovaleva, Oksana A, Chekhonin, Vladimir P, Vassetzky, Yegor S, Avdieiev, Stanislav S, Bakker, Bjorn, Taudt, Aaron S, Belderbos, Mirjam E, Porubsky, David, Spierings, Diana C J, De Jong, Tristan V, Halsema, Nancy, Kazemier, Hinke G, Hoekstra-Wakker, Karina, Bradley, Allan, De Bont, Eveline S J M, Van Den Berg, Anke, Guryev, Victor, Lansdorp, Peter M, Tatché, Maria C, Foijer, Floris, Liehr, Thomas, Baudoin, Nicolaas C, Nicholson, Joshua M, Soto, Kimberly, Quintanilla, Isabel, Camps, Jordi, Cimini, Daniela, Dürrbaum, M., Donnelly, N., Passerini, V., Kruse, C., Habermann, B., Storchová, Z., Mandrioli, Daniele, Belpoggi, Fiorella, Silbergeld, Ellen K, Perry, Melissa J, Skotheim, Rolf I, Løvf, Marthe, Johannessen, Bjarne, Hoff, Andreas M, Zhao, Sen, SveeStrømme, Jonas M, Sveen, Anita, Lothe, Ragnhild A, Hehlmann, R., Voskanyan, A., Fabarius, A., Böcking, Alfred, Biesterfeld, Stefan, Berynskyy, Leonid, Börgermann, Christof, Engers, Rainer, Dietz, Josef, Fritz, A., Sehgal, N., Vecerova, J., Stojkovicz, B., Ding, H., Page, N., Tye, C., Bhattacharya, S., Xu, J., Stein, G., Stein, J., Berezney, R., Gong, Xue, Grasedieck, Sarah, Swoboda, Julian, Rücker, Frank G, Bullinger, Lars, Pollack, Jonathan R, Roumelioti, Fani-Marlen, Chiourea, Maria, Raftopoulou, Christina, Gagos, Sarantis, Duesberg, Peter, Bloomfield, Mat, Hwang, Sunyoung, Gustafsson, Hans T, O’Sullivan, Ciara, Acevedo-Colina, Aracelli, Huang, Xinhe, Klose, Christian, Schevchenko, Andrej, Dickson, Robert C, Cavaliere, Paola, Dephoure, Noah, Torres, Eduardo M, Stampfer, Martha R, Vrba, Lukas, LaBarge, Mark A, Futscher, Bernard, Garbe, James C, Zhou, Yi-Hong, Trinh, Andrew L, and Digman, Michelle
- Subjects
lcsh:Genetics ,610 Medical sciences Medicine ,lcsh:QH426-470 ,Meeting Abstracts - Published
- 2017
30. Diagnostic significance of highly sensitive troponins in cardiac surgery.
- Author
-
YANOVSKAYA, Irina, MANDEL, Irina, KLYPA, Tatiana, KOLYSHKINA, Nadezhda, MAREY, Iliya, ZOTOV, Alexander, and BAKLAUSHEV, Vladimir
- Abstract
The level of troponins after cardiac surgery always exceeds the reference values, however, the interpretation of these changes is difficult. Aim: to determine the relationship between high-sensitivity cardiac troponin I and troponin T levels and the risk of developing heart failure (HF) within 24 hours after heart surgery. A prospective, observational, single-center study included 70 patients undergoing elective heart surgery. Patients were retrospectively divided into two groups based on the development of HF in the first 12 hours after surgery. The levels of highly sensitive Troponin I (HsTI) in patients who underwent elective heart surgery without complications (n=57) were 61 times higher than the upper reference limit, with HF (n=13) - 111 times higher than the upper reference limit. The levels of highly sensitive Troponin T (HsTT) are 25.5 and 51 times higher, respectively. The level of HsTI at the end of the surgery can be a predictor of the development of HF, regardless of the use of cardiopulmonary bypass (threshold value 1483 ng/l), as well as a predictor of the need for inotropic support for 2 days or more, regardless of the type of operation (threshold value 1573 ng/l). There was a direct moderate correlation of HsTI at the end of the operation and 6 hours after the operation with cumulative hemohydrobalance for 24 hours, which was 60% higher in patients with HF than in patients without complications. In this study, we conducted a comparative assessment of troponin concentration with and without CVI. The HsTI levels in patients who underwent elective heart surgery without complications were 61 times higher than the upper limit of normal, whereas with CVI development, these were 111 times higher than the upper limit of normal, and the HsTT levels were 25.5 and 51 times higher, respectively. Threshold values for the prognosis of CVI after heart surgery (with/without CPB) is perhaps the level of HsTI of 1483 ng/L at the end of surgery and the HsTT level of 178 pg/mL 24 h after surgery with CPB. Elevated HsTI level predicts the need for catecholamine support and the probability of a complicated postoperative period earlier than HsTT. In the present study, we revealed the predictive ability of HsTI at the end of surgery and 6 and 24 h after surgery in determining the risk of CVI development and the need for inotropic support for 2 days or more. In the present study, in addition to trying to determine the "signal" level of troponin in cardiac surgery, we identified factors associated with an increase in troponin level and CVI development postoperatively, namely, CPB duration and perioperative infusion volume. Given the relationship between the rise in troponin levels and CPB duration, but not the period of myocardial ischemia, the systemic inflammatory response may influence the level of troponins. A factor in the increase in troponins was a significant positive perioperative hemohydrobalance. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. VAV1‐overexpressing YT cells display improved cytotoxicity against malignant cells.
- Author
-
Smagina, Anna S., Kulemzin, Sergey V., Yusubalieva, Gaukhar M., Kedrova, Anna G., Sanzharov, Andrey E., Ivanov, Yurii V., Matvienko, Darya A., Kalsin, Vladimir A., Gorchakov, Andrey A., Baklaushev, Vladimir P., and Taranin, Aleksandr V.
- Subjects
KILLER cells ,CHIMERIC antigen receptors ,TREATMENT effectiveness ,CELL lines ,TUMOR microenvironment - Abstract
Immunotherapy based on adoptive transfer of genetically engineered T‐ and NK‐cells is an area of active ongoing research and has proven highly efficacious for patients with certain B‐cell malignancies. Use of NK cells and NK cell lines as carriers of chimeric antigen receptors (CARs) appears particularly promising, as this opens an opportunity for moving the therapy from autologous to the allogeneic (universal) format. This "off‐the‐shelf" approach is thought to significantly reduce the price of the treatment and make it available to many more patients in need. Yet, the efficacy of CAR‐NK cells in vivo presently remains low, and boosting the activity of CAR NK cells via stronger tumor homing, resistance to tumor microenvironment, as well as greater cytotoxicity may translate into improved patient outcomes. Here, we established a derivative of a human NK cell line YT overexpressing a positive regulator of cytotoxicity, VAV1. Activity of YT‐VAV1 cells obtained was assayed in vitro against several cancer cell lines and primary patient‐derived cancer cells. YT‐VAV1 cells outperform parental YT cells in terms of cytotoxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. Low Circulating Vitamin D in Intensive Care Unit-Admitted COVID-19 Patients as a Predictor of Negative Outcomes.
- Author
-
Bychinin, Mikhail V, Klypa, Tatiana V, Mandel, Irina A, Andreichenko, Sergey A, Baklaushev, Vladimir P, Yusubalieva, Gaukhar M, Kolyshkina, Nadezhda A, and Troitsky, Aleksandr V
- Subjects
COVID-19 ,HOSPITAL mortality ,FORECASTING ,VITAMIN D ,CRITICAL care medicine ,RESPIRATORY infections ,VITAMIN D deficiency - Abstract
Background: Vitamin D deficiency has been associated with an increased risk of respiratory infections.Objectives: The study aimed to evaluate the serum 25-hydroxyvitamin D [25(OH)D] concentration in patients admitted to the intensive care unit (ICU) as a predictor of coronavirus disease 2019 (COVID-19) mortality.Methods: A single-center retrospective observational study was conducted. Forty adult patients (50% men) with confirmed COVID-19 who were admitted to the ICU were enrolled. The primary endpoint was mortality at day 60. Serum 25(OH)D concentration was measured on the day of admission to the ICU. We used the Mann-Whitney test, Fisher's exact test, Kaplan-Meier analysis, and receiver operator characteristic (ROC) analysis to assess serum 25(OH)D concentration as a predictor of COVID-19 mortality.Results: All 40 patients had a low median (IQR) serum 25(OH)D concentration at admission [12 (9-15) ng/mL]. The median (IQR) serum 25(OH)D concentration was greater in survivors [13.3 (10.0-17.1) ng/mL, n = 22] than in nonsurvivors [9.6 (7.9-14.2) ng/mL; n = 18], P = 0.044. The area under the ROC curve was 0.69 (95% CI: 0.52, 0.86; P = 0.044). The 60-d mortality rate of those with serum 25(OH)D concentrations ≤9.9 ng/mL (n = 14, 71%) tended to be greater than that of those with concentrations >9.9 ng/mL (n = 26, 31%) (P = 0.065), and they had a 5.6-fold higher risk of death (OR: 5.63; 95% CI: 1.35, 23.45; P = 0.018).Conclusions: The ICU patients had a low serum 25(OH)D concentration. Serum 25(OH)D concentrations ≤9.9 ng/mL on admission can be used to predict in-hospital mortality in patients with COVID-19.This trial was registered at clinicaltrials.gov as NCT04450017. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
33. Spidroin Silk Fibers with Bioactive Motifs of Extracellular Proteins for Neural Tissue Engineering.
- Author
-
Revkova, Veronica A., Sidoruk, Konstantin V., Kalsin, Vladimir A., Melnikov, Pavel A., Konoplyannikov, Mikhail A., Kotova, Svetlana, Frolova, Anastasia A., Rodionov, Sergey A., Smorchkov, Mikhail M., Kovalev, Alexey V., Troitskiy, Alexander V., Timashev, Peter S., Chekhonin, Vladimir P., Bogush, Vladimir G., and Baklaushev, Vladimir P.
- Published
- 2021
- Full Text
- View/download PDF
34. Intra-Arterial Stem Cell Transplantation in Experimental Stroke in Rats: Real-Time MR Visualization of Transplanted Cells Starting With Their First Pass Through the Brain With Regard to the Therapeutic Action.
- Author
-
Namestnikova, Daria D., Gubskiy, Ilya L., Revkova, Veronica A., Sukhinich, Kirill K., Melnikov, Pavel A., Gabashvili, Anna N., Cherkashova, Elvira A., Vishnevskiy, Daniil A., Kurilo, Victoria V., Burunova, Veronica V., Semkina, Alevtina S., Abakumov, Maxim A., Gubsky, Leonid V., Chekhonin, Vladimir P., Ahlfors, Jan-Eric, Baklaushev, Vladimir P., and Yarygin, Konstantin N.
- Subjects
STEM cell transplantation ,INTERNAL carotid artery ,BONE marrow cells ,MESENCHYMAL stem cells ,ARTERIAL occlusions - Abstract
Cell therapy is an emerging approach to stroke treatment with a potential to limit brain damage and enhance its restoration after the acute phase of the disease. In this study we tested directly reprogrammed neural precursor cells (drNPC) derived from adult human bone marrow cells in the rat middle cerebral artery occlusion (MCAO) model of acute ischemic stroke using human placenta mesenchymal stem cells (pMSC) as a positive control with previously confirmed efficacy. Cells were infused into the ipsilateral (right) internal carotid artery of male Wistar rats 24 h after MCAO. The main goal of this work was to evaluate real-time distribution and subsequent homing of transplanted cells in the brain. This was achieved by performing intra-arterial infusion directly inside the MRI scanner and allowed transplanted cells tracing starting from their first pass through the brain vessels. Immediately after transplantation, cells were observed in the periphery of the infarct zone and in the brain stem, 15 min later small numbers of cells could be discovered deep in the infarct core and in the contralateral hemisphere, where drNPC were seen earlier and in greater numbers than pMSC. Transplanted cells in both groups could no longer be detected in the rat brain 48–72 h after infusion. Histological and histochemical analysis demonstrated that both the drNPC and pMSC were localized inside blood vessels in close contact with the vascular wall. No passage of labeled cells through the blood brain barrier was observed. Additionally, the therapeutic effects of drNPC and pMSC were compared. Both drNPC and pMSC induced substantial attenuation of neurological deficits evaluated at the 7th and 14th day after transplantation using the modified neurological severity score (mNSS). Some of the effects of drNPC and pMSC, such as the influence on the infarct volume and the survival rate of animals, differed. The results suggest a paracrine mechanism of the positive therapeutic effects of IA drNPC and pMSC infusion, potentially enhanced by the cell-cell interactions. Our data also indicate that the long-term homing of transplanted cells in the brain is not necessary for the brain's functional recovery. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
35. Homogenous and Heterogenous Prognostic Factors for Patients with Bone Sarcoma.
- Author
-
Xu, Guijun, Wu, Haixiao, Xu, Yao, Zhang, Yanting, Lin, Feng, Baklaushev, Vladimir P, Chekhonin, Vladimir P, Peltzer, Karl, Wang, Xin, Mao, Min, Wang, Guowen, Cui, Ping, and Zhang, Chao
- Subjects
OSTEOSARCOMA ,CHORDOMA ,PROGNOSIS ,EWING'S sarcoma ,PROOF & certification of death ,LOG-rank test - Abstract
Objective: The aim of this study was to examine the survival rate of patients with different bone sarcomas and to investigate homogenous and heterogenous prognostic factors for different types of bone sarcomas. Methods: This is a retrospective analysis of records from the Surveillance, Epidemiology, and End Result (SEER) database. Clear information on the distant metastasis of cancer is provided in the SEER database for patients diagnosed between January 2010 and December 2016. Data for the four types of malignant bone sarcomas were extracted, including osteosarcoma, chondrosarcoma, Ewing sarcoma, and chordoma. Patients with bone sarcomas originated from other sites, diagnosed at autopsy, or indicated in death certification were excluded. The overall survival was calculated for the entire cohort and across different bone sarcomas using the Kaplan–Meier method. A subgroup analysis of the different survival rates of four types of bone sarcomas in various levels of each variable was conducted and the differences were tested with the log‐rank test. Cox proportional hazard regression analysis was performed to determine the prognostic factors. Variables with P < 0.05 in the univariate Cox regression analysis were further analyzed using a multivariate Cox regression analysis. The prognostic factors in four groups of bone sarcomas were compared to determine the homogenous and heterogenous factors. Results: A total of 4732 patients were included with a follow up of 25 (0–83) months. The mean age of patients was 39.7 ± 24.1 years. The 1‐year, 3‐year, and 5‐year overall survival rate for the entire cohort was 86.2% (95% confidence interval [CI]: 85.2%–87.2%), 70.5% (95% CI: 68.9%–72.1%), and 63.0% (95% CI: 61.2%–64.8%), respectively. Factors including age older than 40 years, higher grade, regional and distant stage, tumor in the extremities, T2 stage, bone and lung metastases, and non‐surgery were significantly associated with the poor survival of the entire cohort. The mean overall survival duration of patients with chordoma, chondrosarcoma, Ewing sarcoma, and osteosarcoma was 66.86 (95% CI: 64.06–69.66), 63.53 (95% CI: 61.81–65.25), 58.06 (95% CI: 55.49–60.62) and 54.91 (95% CI: 53.14–56.69) months, respectively. Compared with chordoma, the hazard ratio (HR) and 95% CI for patients with chondrosarcoma, Ewing sarcoma, and osteosarcoma were 1.30 (95% CI: 1.04–1.62; P = 0.023), 1.69 (95% CI: 1.33–2.14; P < 0.001), and 2.00 (95% CI: 1.61–2.48; P <0.001), respectively. Different bone sarcomas showed homogenous and heterogenous prognostic factors. Conclusion: Different clinicopathological characteristics and prognoses were revealed in patients with osteosarcoma, chondrosarcoma, Ewing sarcoma, and chordoma. The risk factors can potentially guide prognostic prediction and sarcoma‐specific treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
36. Chitosan-g-oligo(L,L-lactide) Copolymer Hydrogel Potential for Neural Stem Cell Differentiation.
- Author
-
Revkova, Veronica A., Grebenik, Ekaterina A., Kalsin, Vladimir A., Demina, Tatiana S., Bardakova, Kseniia N., Shavkuta, Boris S., Melnikov, Pavel A., Samoilova, Ekaterina M., Konoplyannikov, Mikhail A., Efremov, Yuri M., Zhang, Chao, Akopova, Tatiana A., Troitsky, Alexandr V., Timashev, Peter S., and Baklaushev, Vladimir P.
- Published
- 2020
- Full Text
- View/download PDF
37. Early Death Incidence and Prediction in Stage IV Breast Cancer.
- Author
-
Yumei Zhao, Guijun Xu, Xinpeng Guo, Wenjuan Ma, Yao Xu, Peltzer, Karl, Chekhonin, Vladimir P., Baklaushev, Vladimir P., Nan Hu, Xin Wang, Zheng Liu, and Chao Zhang
- Published
- 2020
- Full Text
- View/download PDF
38. Epidemiology, tumor characteristics and survival in patients with angiosarcoma in the United States: a population-based study of 4537 cases.
- Author
-
Zhang, Chao, Xu, Guijun, Liu, Zheng, Xu, Yao, Lin, Feng, Baklaushev, Vladimir P, Chekhonin, Vladimir P, Peltzer, Karl, Mao, Min, Wang, Xin, and Wang, Guowen
- Published
- 2019
- Full Text
- View/download PDF
39. Gene Encoding Chitinase 3-Like 1 Protein (CHI3L1) is a Putative Oncogene
- Author
-
Kavsan, Vadym M., Baklaushev, Vladimir P., Balynska, Olena V., Iershov, Anton V., Areshkov, Pavlo O., Yusubalieva, Gaukhar M., Grinenko, Nadezhda Ph., Victorov, Ilya V., Rymar, Vadym I., Sanson, Marc, and Chekhonin, Vladimir P.
- Subjects
oncogene ,chitinase 3-like 1 protein (CHI3L1) ,glioblastoma ,Article - Abstract
An important task in understanding oncogenesis is the identification of those genes whose copy number and expression increase during tumorigenesis. Previously, in an effort to identify genes which could be used as molecular markers for glial tumors, we compared gene expression in glioblastoma to the normal brain cells. Among the genes with the most pronounced increased expression in tumors there was CHI3L1, encoding the secreted chitinase 3-like 1 protein (also known as HC gp-39 or YKL-40). Expression of CHI3L1 was found increased significantly in various tumors in comparison with corresponding normal tissues. Here we show that CHI3L1 can decrease the doubling time of 293 cells. We have also demonstrated that CHI3L1 allows the anchorage-independent growth in soft agar and, in addition, stable CHI3L1 expression made 293 cells tumorigenic: these cells stimulate the initiation of tumors after their xenograft transplantation into the Wistar rat brains. Thus, the overexpression of CHI3L1 is likely to be critical in the development of some tumors and when we gain more information about mechanisms of CHI3L1 oncogenicity, it could be used as one of the potential targets for anticancer therapy.
- Published
- 2011
40. Advanced Hepatocellular Carcinoma with Bone Metastases: Prevalence, Associated Factors, and Survival Estimation.
- Author
-
Xu Guo, Yao Xu, Xin Wang, Feng Lin, Haixiao Wu, Jincai Duan, Yuqing Xiong, Xiuxin Han, Baklaushev, Vladimir P., Shunbin Xiong, Chekhonin, Vladimir P., Peltzer, Karl, Guowen Wang, and Chao Zhang
- Published
- 2019
- Full Text
- View/download PDF
41. Real-World Study of the Incidence, Risk Factors, and Prognostic Factors Associated with Bone Metastases in Women with Uterine Cervical Cancer Using Surveillance, Epidemiology, and End Results (SEER) Data Analysis.
- Author
-
Yiran Zhang, Xu Guo, Guowen Wang, Wenjuan Ma, Ruoyan Liu, Xiuxin Han, Lili Li, Baklaushev, Vladimir P., Bryukhovetskiy, Andrey S., Wan Wang, Xin Wang, and Chao Zhang
- Published
- 2018
- Full Text
- View/download PDF
42. Temozolomide promotes genomic and phenotypic changes in glioblastoma cells.
- Author
-
Stepanenko, Aleksei A., Andreieva, Svitlana V., Korets, Kateryna V., Mykytenko, Dmytro O., Baklaushev, Vladimir P., Huleyuk, Nataliya L., Kovalova, Oksana A., Kotsarenko, Kateryna V., Chekhonin, Vladimir P., Vassetzky, Yegor S., Avdieiev, Stanislav S., and Dmitrenko, Vladimir V.
- Subjects
TEMOZOLOMIDE ,GLIOMA treatment ,ANEUPLOIDY ,DRUG resistance in cancer cells ,KARYOTYPES - Abstract
Background: Temozolomide (TMZ) is a first-line drug for the treatment of glioblastoma. Long-term TMZ-treated tumour cells acquire TMZ resistance by profound reprogramming of the transcriptome, proteome, kinome, metabolism, and demonstrate versatile and opposite changes in proliferation, invasion, in vivo growth, and drug crossresistance. We hypothesized that chromosomal instability (CIN) may be implicated in the generation of TMZ-driven molecular and phenotype diversity. CIN refers to the rate (cell-to-cell variability) with which whole chromosomes or portions of chromosomes are gained or lost. Methods: The long-term TMZ-treated cell lines were established in vitro (U251TMZ1, U251TMZ2, T98GTMZ and C6TMZ) and in vivo (C6R2TMZ). A glioma model was achieved by the intracerebral stereotactic implantation of C6 cells into the striatum region of rats. Genomic and phenotypic changes were analyzed by conventional cytogenetics, array CGH, trypan blue exclusion assay, soft agar colony formation assay, scratch wound healing assay, transwell invasion assay, quantitative polymerase chain reaction, and Western blotting. Results: Long-term TMZ treatment increased CIN-mediated genomic diversity in U251TMZ1, U251TMZ2 and T98GTMZ cells but reduced it in C6TMZ and C6R2TMZ cells. U251TMZ1 and U251TMZ2 cell lines, established in parallel with a similar treatment procedure with the only difference in the duration of treatment, underwent individual phenotypic changes. U251TMZ1 had a reduced proliferation and invasion but increased migration, whereas U251TMZ2 had an enhanced proliferation and invasion but no changes in migration. U251TMZ1 and U251TMZ2 cells demonstrated individual patterns in expression/activation of signal transduction proteins (e.g., MDM2, p53, ERK, AKT, and ASK). C6TMZ and C6R2TMZ cells had lower proliferation, colony formation efficiency and migration, whereas T98GTMZ cells had increased colony formation efficiency without any changes in proliferation, migration, and invasion. TMZ-treated lines demonstrated a differential response to a reduction in glucose concentration and an increased resistance to TMZ re-challenge but not temsirolimus (mTOR inhibitor) or U0126 (MEK1/2 inhibitor) treatment. Conclusion: Long-term TMZ treatment selected resistant genotype-phenotype variants or generated novel versatile phenotypes by increasing CIN. An increase of resistance to TMZ re-challenge seems to be the only predictable trait intrinsic to all long-term TMZ-treated tumour cells. Changes in genomic diversity may be responsible for heterogeneous phenotypes of TMZ-treated cell lines. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
43. Treatment of glioma by cisplatin-loaded nanogels conjugated with monoclonal antibodies against Cx43 and BSAT1.
- Author
-
Baklaushev, Vladimir P., Nukolova, Natalia N., Khalansky, Alexander S., Gurina, Olga I., Yusubalieva, Gaukhar M., Grinenko, Nadejhda Ph., Gubskiy, Ilya L., Melnikov, Pavel A., Kardashova, Karina Sh., Kabanov, Alexander V., and Chekhonin, Vladimir P.
- Subjects
- *
CONNEXIN 43 , *DRUG delivery systems , *BRAIN tumor treatment , *MEMBRANE proteins , *GLIOMA treatment , *LABORATORY rats - Abstract
Targeted drug delivery for brain tumor treatment is one of the important objectives in nanomedicine. Human glioblastoma is the most frequent and aggressive type of brain tumors. The preferential expression of membrane protein connexin 43 (Cx43) and brain-specific anion transporter (BSAT1) in the tumor and peritumoral area is a key component for targeted drug delivery. The purpose of this study was to design cisplatin-loaded nanogels conjugated with monoclonal antibodies to Cx43 and BSAT1 for treatment of intracranial gliomas 101/8. MRI volumetric analysis of tumor-bearing rats indicated significantly reduced tumor volume with cisplatin-loaded targeted-nanogel treatment compared to other formulations. The median survival of rats treated with targeted nanogels conjugated with specific mAbs against extracellular loops of Cx43 and BSAT1 were 27 and 26.6 days higher than that in control group, respectively. For the first time we demonstrated the efficiency of mAb-targeted cisplatin-loaded nanogels in the experimental model of glioma 101/8. This approach could facilitate the development of new drug delivery systems for the treatment of gliomas. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
44. Visualization of Connexin 43-positive cells of glioma and the periglioma zone by means of intravenously injected monoclonal antibodies.
- Author
-
Baklaushev, Vladimir P., Yusubalieva, Gaukhar M., Tsitrin, Eugene B., Gurina, Olga I., Grinenko, Nadezhda Ph., Victorov, Ilya V., and Chekhonin, Vladimir P.
- Subjects
- *
CONNEXINS , *MONOCLONAL antibodies , *GLIOMAS , *INTRAVENOUS injections , *GAP junctions (Cell biology) - Abstract
The selectivity of monoclonal antibodies against the E2 extracellular fragment of connexin 43 (Cx43) for a glioma focus was studied in in vivo experiments on animals with intracranial C6 glioma. Antibodies labeled with two alternative labels, the radioisotope 125I and the fluorophore Alexa 660, were intravenously injected to rats with 18-day gliomas. Seventy-two hours after injection, 125I-labeled antibodies accumulated in the hemisphere where the glioma was located to a concentration of 0.27 ±± 0.01% of the injected dose per gram of wet weight, which exceeded their accumulation in the liver, spleen, and other organs. Fluorescent-labeled antibodies against the Cx43 fragment E2 specifically visualized cells in the peritumoral astroglial bank (a zone of active invasion of glioma cells). Double immunofluorescent visualization using antibodies against the Cx43 fragment E2 and glial fibrillar acidic protein (GFAP) showed that only a small proportion of the cells that bound the antibodies injected into the blood circulation were reactive astrocytes, whereas most of these cells were GFAP-negative and morphologically corresponded to astroblasts. These results suggest that antibodies against the extracellular Cx43 fragment E2 can be used for targeted transport of diagnostic and therapeutic drugs to the peritumoral invasion zone of high-grade gliomas. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
45. Epigenetic Clock and Circadian Rhythms in Stem Cell Aging and Rejuvenation.
- Author
-
Samoilova, Ekaterina M., Belopasov, Vladimir V., Ekusheva, Evgenia V., Zhang, Chao, Troitskiy, Alexander V., and Baklaushev, Vladimir P.
- Subjects
CELLULAR aging ,CIRCADIAN rhythms ,CLOCK genes ,STEM cells ,STEM cell niches ,EPIGENETICS - Abstract
This review summarizes the current understanding of the interaction between circadian rhythms of gene expression and epigenetic clocks characterized by the specific profile of DNA methylation in CpG-islands which mirror the senescence of all somatic cells and stem cells in particular. Basic mechanisms of regulation for circadian genes CLOCK-BMAL1 as well as downstream clock-controlled genes (ССG) are also discussed here. It has been shown that circadian rhythms operate by the finely tuned regulation of transcription and rely on various epigenetic mechanisms including the activation of enhancers/suppressors, acetylation/deacetylation of histones and other proteins as well as DNA methylation. Overall, up to 20% of all genes expressed by the cell are subject to expression oscillations associated with circadian rhythms. Additionally included in the review is a brief list of genes involved in the regulation of circadian rhythms, along with genes important for cell aging, and oncogenesis. Eliminating some of them (for example, Sirt1) accelerates the aging process, while the overexpression of Sirt1, on the contrary, protects against age-related changes. Circadian regulators control a number of genes that activate the cell cycle (Wee1, c-Myc, p20, p21, and Cyclin D1) and regulate histone modification and DNA methylation. Approaches for determining the epigenetic age from methylation profiles across CpG islands in individual cells are described. DNA methylation, which characterizes the function of the epigenetic clock, appears to link together such key biological processes as regeneration and functioning of stem cells, aging and malignant transformation. Finally, the main features of adult stem cell aging in stem cell niches and current possibilities for modulating the epigenetic clock and stem cells rejuvenation as part of antiaging therapy are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
46. Osteopontin Induces the Extension of Epidural Fibrosis into the Spinal Canal.
- Author
-
Chao Zhang, Baklaushev, Vladimir P., Alexandnovich, Melnikov P., Shiqing Feng, Bryukhovetskiy, Andrey S., and Chekhonin, Vladimir P.
- Published
- 2015
47. Osteopontin induces the extension of epidural fibrosis into the spinal canal.
- Author
-
Zhang, Chao, Baklaushev, Vladimir P, Alexandnovich, Meinikov P, Feng, Shiqing, Bryukhovetskiy, Andrey S, and Chekhonin, Vladimir P
- Published
- 2015
48. Recombinant Strains of Oncolytic Vaccinia Virus for Cancer Immunotherapy.
- Author
-
Shakiba Y, Vorobyev PO, Mahmoud M, Hamad A, Kochetkov DV, Yusubalieva GM, Baklaushev VP, Chumakov PM, and Lipatova AV
- Subjects
- Vaccinia virus genetics, Immunotherapy, Gene Editing, Genome, Viral, Oncolytic Viruses genetics, Neoplasms therapy
- Abstract
Cancer virotherapy is an alternative therapeutic approach based on the viruses that selectively infect and kill tumor cells. Vaccinia virus (VV) is a member of the Poxviridae, a family of enveloped viruses with a large linear double-stranded DNA genome. The proven safety of the VV strains as well as considerable transgene capacity of the viral genome, make VV an excellent platform for creating recombinant oncolytic viruses for cancer therapy. Furthermore, various genetic modifications can increase tumor selectivity and therapeutic efficacy of VV by arming it with the immune-modulatory genes or proapoptotic molecules, boosting the host immune system, and increasing cross-priming recognition of the tumor cells by T-cells or NK cells. In this review, we summarized the data on bioengineering approaches to develop recombinant VV strains for enhanced cancer immunotherapy.
- Published
- 2023
- Full Text
- View/download PDF
49. Alterations in the CD56 - and CD56 + T Cell Subsets during COVID-19.
- Author
-
Vavilova JD, Ustiuzhanina MO, Boyko AA, Streltsova MA, Kust SA, Kanevskiy LM, Iskhakov RN, Sapozhnikov AM, Gubernatorova EO, Drutskaya MS, Bychinin MV, Novikova ON, Sotnikova AG, Yusubalieva GM, Baklaushev VP, and Kovalenko EI
- Subjects
- Humans, T-Lymphocyte Subsets, Killer Cells, Natural, Cell Differentiation, CD8-Positive T-Lymphocytes, COVID-19 metabolism
- Abstract
The effectiveness of the antiviral immune response largely depends on the activation of cytotoxic T cells. The heterogeneous group of functionally active T cells expressing the CD56 molecule (NKT-like cells), that combines the properties of T lymphocytes and NK cells, is poorly studied in COVID-19. This work aimed to analyze the activation and differentiation of both circulating NKT-like cells and CD56
- T cells during COVID-19 among intensive care unit (ICU) patients, moderate severity (MS) patients, and convalescents. A decreased proportion of CD56+ T cells was found in ICU patients with fatal outcome. Severe COVID-19 was accompanied by a decrease in the proportion of CD8+ T cells, mainly due to the CD56- cell death, and a redistribution of the NKT-like cell subset composition with a predominance of more differentiated cytotoxic CD8+ T cells. The differentiation process was accompanied by an increase in the proportions of KIR2DL2/3+ and NKp30+ cells in the CD56+ T cell subset of COVID-19 patients and convalescents. Decreased percentages of NKG2D+ and NKG2A+ cells and increased PD-1 and HLA-DR expression levels were found in both CD56- and CD56+ T cells, and can be considered as indicators of COVID-19 progression. In the CD56- T cell fraction, increased CD16 levels were observed in MS patients and in ICU patients with lethal outcome, suggesting a negative role for CD56- CD16+ T cells in COVID-19. Overall, our findings suggest an antiviral role of CD56+ T cells in COVID-19.- Published
- 2023
- Full Text
- View/download PDF
50. Oncolytic therapy with recombinant vaccinia viruses targeting the interleukin-15 pathway elicits a synergistic response.
- Author
-
Shakiba Y, Vorobyev PO, Yusubalieva GM, Kochetkov DV, Zajtseva KV, Valikhov MP, Kalsin VA, Zabozlaev FG, Semkina AS, Troitskiy AV, Baklaushev VP, Chumakov PM, and Lipatova AV
- Abstract
We developed recombinant variants of oncolytic vaccinia virus LIVP strain expressing interleukin-15 (IL-15) or its receptor subunit alpha (IL-15Rα) to stimulate IL-15-dependent immune cells. We evaluated their oncolytic activity either alone or in combination with each other in vitro and in vivo using the murine CT26 colon carcinoma and 4T1 breast carcinoma models. We demonstrated that the admixture of these recombinant variants could promote the generation of the IL-15/IL-15Rα complex. In vitro studies indicated that 4T1 breast cancer cells were more susceptible to the developed recombinant viruses. In vivo studies showed significant survival benefits and tumor regression in 4T1 breast cancer syngeneic mice that received a combination of LIVP-IL15-RFP with LIVP-IL15Ra-RFP. Histological analysis showed recruited lymphocytes at the tumor region, while no harmful effects to the liver or spleen of the animals were detected. Evaluating tumor-infiltrated lymphocytes represented profound activation of cytotoxic T cells and macrophages in mice receiving combination therapy. Thus, our experiments showed superior oncolytic effectiveness of simultaneous injection of LIVP-IL15-RFP and LIVP-IL15Ra-RFP in breast cancer-bearing mice. The combined therapy by these recombinant variants represents a potent and versatile approach for developing new immunotherapies for breast cancer., Competing Interests: The authors report no conflicts of interest in this work., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.